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Background: Cholestyramine enhances gallbladder emptying and plasma cholecystokinin responses to 
oral ingestion of a mixed meal. It is not known whether this effect occurs independently of alterations in 
gastric emptying or maldigestion of nutrients. Methods: We perfused 15 g of an amino acid meal 
intraduodenally for 60 min in seven healthy volunteers, once with and once without cholestyramine, 
Intraduodenal perfusion of saline with or without cholestyramine (6 g/h) was started 60 min before the 
amino acid meal and continued for 2h. Results: Cholestyramine markedly enhanced the incremental 
plasma cholecystokinin response to the meal from 36 ±  12 to 139 ± 25pmol/1 - 60min (P < 0.005), 
incremental amylase output from 2.4 ±  0.7 to 5.7 ±  0.7 kU/h (.P < 0.05), and incremental integrated 
gallbladder contraction from 1948 ±  235 to 2840 ±  189% * 60 min (P < 0.05). Conclusion: The enhanc­
ing effect of cholestyramine on postprandial gallbladder contraction, pancreatic enzyme secretion, and 
plasma cholecystokinin release is not dependent on gastric emptying rates or appropriate digestion of 
nutrients.
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The anion exchanger cholestyramine precipitates bile salts. 
Cholestyramine is a drug used in clinical practice to lower 
plasma cholesterol levels, to treat obstructive liver diseases, 
or to decrease diarrhoea induced by bile salt overflow into the 
colon. Recently, cholestyramine has also been used as a tool 
in physiologic studies to investigate the role of bile salts in the 
regulation of plasma cholecystokinin (CCK) release and 
pancreaticobiliary secretion (1-5).
In physiologic studies that used cholestyramine to pre­
cipitate bile acids, cholestyramine enhanced plasma CCK 
levels and gallbladder responses to an orally or intraduoden- 
ally administered mixed meal (1-4) and to bombesin infusion 
(5). Direct effects of cholestyramine on these functions are 
unlikely, since colestipol, a bile salt-binding resin with a 
different molecular structure from cholestyramine, has 
comparable effects on CCK release and gallbladder motility 
(5). Nevertheless» cholestyramine may indirectly affect 
gallbladder motility and plasma CCK release by enhancing 
gastric emptying (6) or by delaying the digestion of fatty 
nutrients (1). To investigate these possibilities, we have 
studied the effect of cholestyramine on plasma CCK and 
pancreatic polypeptide (PP) levels, gallbladder motility, and
pancreatic enzyme secretion in response to a meal stimulus. 
To avoid indirect effects induced by gastric emptying, both 
cholestyramine and the meal stimulus were administered 
intraduo denally. To avoid effects of cholestyramine on the 
hydrolysis of nutrients induced by bile salt precipitation, an 
amino acid mixture was used as meal stimulus,
MATERIALS AND METHODS 
Subjects
Seven healthy volunteers (three women and four men; 
median age, 23 years; range, 19-26 years) participated in the 
studies. None of the volunteers was taking any medication or 
had a history of gastrointestinal symptoms or surgery. The 
study protocol was approved by the ethical committee of the 
University Hospital of Nijmegen, and all subjects gave their 
written informed consent before entering the study.
Reagents
Cholestyramine (Questran®) was obtained from Bristol 
Meijers, Woerden, The Netherlands, as packets containing 4 g 
of the resin; radioiodinated porcine pancreatic polypeptide
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Fig. 1. Study protocol for the two experiments performed in random 
order on different days. In both experiments saline was continuously 
perfused intraduodenally together with the recovery marker 
polyethylene glycol 4000 for 3 h< In one experiment cholestyramine 
(6 g/h) was added to the saline during the last 2h. In both 
experiments 15 g of an amino acid mixture, in the same molecular 
composition as albumin, was perfused intraduodenally during the 
last test hour. Asterisks denote time points when blood was drawn 
for measurement of plasma cholecystokinin and pancreatic poly­
peptide, and gallbladder volume was measured with ultrasonogra­
phy. Crosses denote time points when duodenal juice was sampled 
for the determination of amylase output.
(125I-PPP) was obtained from Novo Nordisk AS, Bagsvaerd, 
Denmark; synthetic CCK33 from Peninsula Laboratories 
Europe, Ltd,, St. Helens, UK; (125I)hy droxyphenylpropionic 
acid-succinimide ester (Bolton-Hunter reagent) from New 
England Nuclear, Boston, Mass., USA; Pharmacia Decanting 
Suspension no. 3 from Pharmacia Diagnostics, AB, Uppsala, 
Sweden; human PP and L-ami no acids from Sigma Chemical 
Co., St. Louis, Mo., USA; and PEG-4000 from BDH, Ltd., 
Poole, UK; all other materials were obtained from Merck, 
Amsterdam, The Netherlands.
Study protocol
After a 12-h fasting period, the volunteers presented at the 
laboratory at 0730 h. In random order, two experiments were 
performed separated from each other by at least 1 week. At 
the beginning of each test a double-lumen polyvinyl tube with 
an outer diameter of 5.7 mm was positioned in the duodenum. 
The proximal lumen of the tube was positioned at the level of 
the papilla Vateri and the distal lumen at the ligament of 
Treitz. The position of the tube was verified by fluoroscopy. 
In addition, an indwelling intravenous catheter was placed in 
a forearm. The catheter was kept patent by a heparin-saline 
solution and was used for the collection of blood samples. The 
following tests were performed:
Test 1: Saline (300 mOsmol/1) was continuously perfused 
intraduodenally for 3h (300 ml/h) together with the recovery 
marker polyethylene glycol 4000 (PEG-4000; 6 g/1). During 
the 3rd test hour, 15 g of an amino acid solution in the same 
molecular composition as albumin (7) was perfused intra­
duodenally, together with saline (Fig. 1).
Test 2 was performed in accordance with the same protocol 
as test 1. However, 1 h after the start of saline perfusion 
cholestyramine (6 g/h) was perfused intraduodenally during 
the last 2 test hours (Fig* 1). This dosage of cholestyramine 
was chosen because previous studies indicated that this 
amount was sufficient to enhance plasma CCK and pancreati- 
cobiliary responses to a meal in humans (2, 3). On the basis of 
in vitro binding studies we calculated that 6 g of cholestyr­
amine could bind approximately one pool of bile salts in 
humans (8, 9). Five-millilitre samples of duodenal contents 
were taken from the tip of the tube during 15-min periods by 
spot-sampling (10) and kept on ice. Blood samples were taken 
every 30 min during the Isth and subsequently every 15 min 
until the end of the test period (Fig. 1).
Blood was collected in ice-chilled glass tubes containing
2 g/1 of ethylenediaminetetraacetate (EDTA). After the 
experiments the blood samples were centrifuged at 4°C for
10 min at 3000 g. Plasma and duodenal samples were stored at 
—20°C until assayed for CCK, PP, PEG-4000, and amylase. 
Each time a blood sample was drawn, two longitudinal and 
two transverse images of the gallbladder were obtained by 
real-time ultrasonography.
Plasma samples
Plasma CCK was measured by a sensitive and specific 
radioimmunoassay (RIA) as described previously (11,12). 
The antibody used (T204) binds to biologically active CCK 
peptides containing the sulphated tyrosine region. On a molar 
base, sulphated gastrins cross-reacted < 2% in the assay, while 
no cross-reactivity with unsulphated gastrins or structurally 
unrelated peptides was found. The detection limit of the assay 
was between 0.5 and 1.0pmol/l CCK in plasma. The intra­
assay precision ranged from 416% to 11,5% in the steep part of 
the standard curve. All measurements of plasma CCK levels 
were performed in the same run.
Plasma PP levels were also determined by RIA (13). The 
antibody used showed no cross-reactivity with structurally 
related gastrointestinal regulatory peptides like peptide YY 
(PYY) or neuropeptide Y (NPY) or with structurally unrelated 
peptides. The detection limit of the assay was 0.5 pmol/I of 
incubation mixture. The intra-assay variation ranged from 4% 
to 7% in the steep part of the standard curve. All measure­
ments of plasma PP levels were performed in one run.
Duodenal samples
Duodenal samples were analysed for PEG-4000 (14) and 
amylase activity (15). Flow rates passing the distal duodenal 
sampling site were calculated on the basis of known perfusion 
rates and PEG-4000 concentrations at the perfusion and 
sampling ports (10). Outputs of amylase were calculated from 
the product of enzyme activity and flow rates. Furthermore, to 
exclude a possible direct effect of cholestyramine on the 
amount of free amino acid concentrations, duodenal samples 
taken during the last test hour were analysed for the amount of 
free amino acids by ion-exchange chromatography (7,16).
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the first 60-min period (-60 to Omin). Subsequently, 
incremental integrated CCK, PP, and gallbladder contraction 
to the amino acid meal was calculated by subtracting the 
integrated response in the basal period (0-60 min) from the 
integrated response in the period of stimulation (60-120 min) 
in each experiment. Similarly, incremental amylase outputs 
were calculated by subtraction of the total output in the basal 
period (0-60 min) from the total output in the period of 
stimulation (60-120 min). Results are expressed as mean 
±  standard error (5s). Statistical analysis was performed with 
Student’s t test for paired results. Differences with a two- 
tailed probability (P) value of less than 0.05 were considered 
significant (20).
Time (min)
Fig. 2. Basal and amino acid-stimulated (60-120 min) plasma 
cholecystokinin (CCK) concentrations (pmol/1) in seven healthy 
subjects either with ( # )  or without (O) intraduodenal administra­
tion (0-120 min) of cholestyramine at a dose of 6 g/h. Values are 




Basal plasma CCK levels were unaffected by saline 
perfusion with or without cholestyramine and varied between
2.4 and 3.0 pmol/1 during the first 2h in both experiments 
(Fig. 2). Perfusion of the amino acid solution caused a rise in 
plasma CCK levels from 2.9 ±  0.2 to a maximum of
Longitudinal and transverse images of the gallbladder were 3.6 ±  0.5 pmol/1, achieved 15 min after the start of amino 
obtained by real-time ultrasonography (Sonolayer Sal 77-B, acid perfusion. Thereafter plasma CCK levels decreased to 
Toshiba, Japan) using a 3.75-MHz transducer (17,18). 3.1 ±  0.3 pmol/1 during the last 45 min of the 3rd test hour. 
Gallbladder volume was calculated from these images by Perfusion of cholestyramine markedly enhanced amino acid- 
the sum of cylinders method using a computer system (19). stimulated CCK levels to 5.2 ±0.7 pmol/1 15 min after the
start of amino acid perfusion. Furthermore, plasma CCK 
levels did not decrease in the last 45 min of the test hour but 
even tended to increase (Fig. 2). As a result, incremental 
Statistical analysis integrated levels (Table I) during amino acid perfusion
All measurements were performed in duplicate, and the differed between the test without and with cholestyramine 
mean of these two measurements was used for further analysis (36 ±  12 versus 139 ±  25 pmol/1 • 60 min; P < 0.01). 
of results. Gallbladder volume was expressed in millilitres
and as a percentage of the mean volume obtained in the lsth  Plasma PP concentrations
The variation of volume measurements ranged from 6% to 
22%.
of the experiment (—60 to Omin). Integrated plasma CCK, Basal plasma PP levels were not affected by saline
PP, and gallbladder responses were determined by calculating perfusion with or without cholestyramine (Fig. 3) and varied
the area under the CCK, PP, or gallbladder contraction time 
curves after subtraction of the mean of the values obtained in
between 17 and 22 pmol/1. Perfusion of amino acids caused 
small increases (P < 0.05) of PP from 18 dz 2 to a maximum
Table I. Integrated responses to intraduodenal perfusion of saline (Sal) with and without cholestyramine (CH) in the basal period (0-60 min) 
and to intraduodenal perfusion of amino acids with or without cholestyramine (60-120 min)
Test 0-60 min 60-120 min Incremental
CCK (pmol/1 60 min) Sal - 9  ± 6 27 ±  l i t 36 ±  12
Sal + CH - 6  ± 8 133 ±  30+$ 139 ±  251
PP (pmol/1 60 min) Sal -2 0  ±  90 648 ±  143 t 669 ±216
Sal + CH 3 ±  140 3172 ±  1006+$ 3169 ±  982f
GBC* {% 60 min) Sal -121  ±  121 1827 ±217$ 1948 ±235
Sal + CH 748 ±  352f 3589 ±  374++ 2840 ±  189t
Amylase (kU) Sal 2.8 ±  0.9 5.2 ±0.7$ 2.4 ±  0.7
Sal + CH 4.0 ±  1.3 9.7 ±1.6+4 5.7 ±  0.7+
Data are mean ±  s* SBM from seven healthy subjects; incremental responses were obtained by subtraction of integrated values in the basal 
period (0-60 min) from integrated values in the period of stimulation (60-120 min).
* GBC = gallbladder contraction, 
t  P < 0.05 versus saline perfusion.
$ P <  0.05 versus 0-60 min.
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Fig. 3. Basal and amino acid-stimulated (60-120 min) plasma 
pancreative polypeptide (PP) concentrations (pmol/1) in seven 
healthy subjects either with (# )  or without (O ) intraduodenal 
administration (0-120 min) of cholestyramine at a dose of 6 gAi. 
Values are expressed as mean ±  s%.
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Fig. 5. Basal and amino acid-stimulated (60-120 min) amylase 
output (kU/15min) in seven healthy subjects either with ( # )  or 
without (O ) intraduodenal administration (0-120 min) of cholestyr­
amine at a dose of 6 g/h. Values are expressed as mean ±
of 37 ±  7 pmol/l 30 min after the start of amino acid 
perfusion. Ingestion of cholestyramine markedly increased
I), Amino acid perfusion resulted in gallbladder contraction 
from 35 ±  3 ml to a minimum of 19 ±  2 ml 45 min after the
plasma PP levels to a maximum of 90 ±  22 pmol/1 45 min start of amino acid perfusion. Cholestyramine further
after the start of amino acid perfusion. As a result, incremental decreased gallbladder volume to a minimum of 7 ±  2 ml 
integrated plasma PP levels (Table I) during amino acid 60 min after the start of amino acid perfusion, Incremental
perfusion were enhanced by cholestyramine (669 ±216 integrated gallbladder contraction following amino acid
versus 3169 d= 982 pmol/1 • 60 min; P < 0.05). perfusion (Table I) was markedly enhanced by cholestyr­
amine (1948 ±  235 versus 2840 dt 189% • 60 min; P < 0.05),
Gallbladder volume
Perfusion of saline did not affect basal gallbladder volume Pancreatic enzyme output
(37 ± 4  ml) (Fig. 4). Mean basal gallbladder volume de~ Basal amylase output (Fig. 5) during saline perfusion was
creased (P < 0.05) from 35 ±  3 ml at the start to 25 d= 4 ml not significantly changed by cholestyramine (2,8 ±0 .9  versus 
1 h after perfusion of cholestyramine (P < 0.05 versus saline), 4.0 ±1.3  kU/h). Amino acid-stimulated amylase output was 
while integrated gallbladder contraction increased (P < 0.05) enhanced by cholestyramine (5.2 ±  0.7 versus 9.7 ±1.6  kU/ 
from —121 ±  121% • 60 min to 748 ±  352% * 60 min (Table h; P < 0.05). As a result, incremental amylase output was also
enhanced (P < 0.05) in the cholestyramine experiment when














Amino acid analysis in duodenal juice
Perfusion of cholestyramine together with amino acids did 
not affect free amino acid concentrations in duodenal juice at 
90 min (Table II). Furthermore, similar amounts of free amino 
acids were found in the amino acid meal with and without 
cholestyramine at all other time points during the last test 
hour (60, 75, 105, and 120 min; data not shown).
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Fig. 4. Basal and amino acid-stimulated (60-120 min) gallbladder 
motility (ml) in seven healthy subjects either with ( # )  or without
(O) intraduodenal administration (0-120 min) of cholestyramine at 
a dose of 6 g/h. Values are expressed as mean ±
DISCUSSION
The present study shows that pancreatic enzyme secretion and 
gallbladder contraction as well as plasma CCK and PP release 
in response to an intraduodenally administered amino acid 
meal are enhanced by duodenal perfusion of cholestyramine 
in humans.
The experimental protocol of the present study differs in 
several aspects from those of previous studies (1-5). First, a
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Table II. Free essential amino acids present in duodenal juice (mmol/ 
1) at 90 min when amino acids either without or with cholestyramine 
were perfused
Amino acids Amino acids -1- cholestyramine
V aline 7.6 ±  0.8 7.5 ±  0.8
Methionine 0.6 ± 0.1 0.6 ±  0.1
Phenylalanine 6.5 ±  0.6 6.3 ±  0.5
Leucine 13.3 ±  1.5 12.7 ±  1.2
Isoleucine 2.6 ±  0.3 2.6 ±  0.2
Tyrosine 2.1 ± 0.1 2.3 ±  0.2
Lysine 18.8 ±  1.5 16.8 ± 3 .5
Histidine 4.4 ±  0.4 4.6 ±  0.3
Data are mean ±  for seven healthy subjects.
basal period of 60 min with or without intraduodenal 
administration of cholestyramine preceded the meal-stimula- 
tion period. Therefore, in contrast with previous studies, this 
protocol enables us to differentiate between effects of 
cholestyramine on unstimulated and on meal-stimulated 
functions. The results demonstrate that cholestyramine sig­
nificantly induces gallbladder contraction under unstimulated 
conditions and tends to cause pancreatic enzyme secretion 
without affecting plasma CCK and PP release. Therefore, the 
enhancing effect of cholestyramine on meal-stimulated 
gallbladder contraction and pancreatic enzyme secretion, 
but not on CCK and PP release, might in part be explained 
by the effect of cholestyramine on these variables in the basal 
state.
Second, the meal and the cholestyramine were adminis­
tered intraduodenally in this study. Intraduodenal adminis­
tration excludes possible effects of cholestyramine on gastric 
factors like gastric emptying, which may interfere with the 
ultimate results (21). The persistence of the enhancing effects 
of cholestyramine after intraduodenal administration indi­
cates that cholestyramine can exert its effects independently 
of gastric factors. Only one other study in humans investi­
gated intraduodenal administration of a meal (3). However, in 
that study a mixed meal containing whole protein and fat was 
used.
Finally, in our study an amino acid mixture was perfused 
intraduodenally. This elemental meal has the advantage that 
cholestyramine cannot interfere with the digestion of fat or 
protein, which is essential for stimulation of gallbladder 
contraction and CCK release (7). This is important because it 
has been suggested that the effect of cholestyramine is 
mediated by insufficient formation of micelles as a result of 
intraluminal bile salt sequestration or by binding of fatty acids
(1). This may result in malabsorption of fat and subsequently 
lead to the exposure of an increased surface are a of the 
proximal intestinal mucosa to CCK-stimulating fatty nutrients 
for a prolonged time (1), The present data indicate that the 
enhancing effect of cholestyramine is not necessarily related 
to fatty nutrients but persists with an amino acid mixture and 
therefore indicates that other mechanisms are involved.
Similar to previous studies plasma PP responses paralleled
plasma CCK responses to cholestyramine under basal and 
meal-stimulated conditions (1). Because circulating CCK 
may induce PP release (22-24), the effect of cholestyramine 
on PP can at least in part be attributed to the increased CCK 
release. Similarly, the enhanced pancreaticobiliary response 
to the amino acid meal with cholestyramine may be explained 
by the increased plasma CCK levels (18,25-27). However, in 
the present study we also found that cholestyramine tended to 
increase pancreatic enzyme secretion and significantly stimu­
lated gallbladder contraction under basal conditions. The 
mechanism by which cholestyramine affected pancreatic 
enzyme secretion and gallbladder motility in the present 
study was probably not related to plasma CCK, since plasma 
CCK levels were not significantly altered. Another possibility 
is that the effect of cholestyramine under basal conditions was 
mediated by activating vagal cholinergic pathways (28, 29). 
However, absence of PP secretion in response to cholestyr­
amine does not support this hypothesis. PP is a hormone that 
is primarily regulated by vagal cholinergic mechanisms 
(30,31). Therefore, other hormonal or neural mechanisms 
are probably involved in mediating the effect of cholestyr­
amine under basal conditions.
The mechanism by which cholestyramine enhanced the 
plasma CCK response to the amino acid meal remains 
speculative. Theoretically, cholestyramine may bind amino 
acids and thereby delay the absorption of CCK-stimulating 
substances, which may in turn trigger CCK cells to increased 
secretion. This possibility was excluded by the presence of 
similar concentrations of free amino acids in both the study 
with and that without cholestyramine.
The results of several studies provide evidence that 
cholestyramine most probably augments CCK release by 
precipitating bile salts in the small bowel. Colestipol, another 
bile salt sequestrant with a chemical structure that is not 
related to cholestyramine, had similar effects (5). Total 
diversion of bile in dogs significantly increased the release 
of CCK in response to intraduodenal administration of amino 
acids, while replacement of the bile salt pool with intraduo­
denal administration of taurocholate reversed the enhance­
ment effect (2). Release of cholecystokinin in response to oral 
amino acids in humans was significantly inhibited by oral 
taurocholate (2). Chenodeoxycholic acid inhibited CCK 
release in response to an intraduodenal mixed liquid meal in 
humans and prevented the enhancement effect of cholestyr­
amine (3). Administration of CCK receptor antagonists in 
humans results in a marked exaggeration of meal-stimulated 
plasma CCK levels (25-27). Because CCK receptor antago­
nists inhibit gallbladder contraction to a greater extent than 
pancreatic enzyme secretion in humans, this suggests that the 
effect is primarily due to a decreased amount of bile salts in 
the small bowel (27, 32).
The mechanism by which bile acids inhibit amino acid- 
stimulated CCK release is not known. Bile acids may interfere 
with the stimulatory action of amino acids on CCK release by 
slowing down amino acid absortion, resulting in an increased
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surface area of small-intestinal mucosa exposed to stimu­
lating nutrients. However, Dimagno did not observe accelera­
tion of amino acid absorption by bile salts (32, 33). Further­
more, the finding that cholestyramine also enhances 
bombesin-stimulated plasma CCK levels indicates that the 
effect is not dependent on the presence of nutrients in the gut. 
Whether the effect of bile acids is mediated by other factors 
such as a CCK releasing factor or by inhibitory hormones 
such as somatostatin remains to be established (34-36).
In conclusion, the present study demonstrates that the 
enhancing effect of cholestyramine on meal-stimulated 
gallbladder contraction, pancreatic enzyme secretion, and 
CCK and PP release is independent of gastric emptying and 
the hydrolysis of nutrients.
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